We have developed a formulation based on graphene oxide that inhibits the formation of lung cancer cells forcing it to disintegrate into non-cancer forming cells.
Why have we adopted the graphene oxide formulation? Graphene oxide and its functional derivatives exhibit a unique set of physical properties that are mostly used to convey therapeutic agents including antibodies, DNA, proteins, small molecules of drugs and genes. Graphene oxide has properties that are relevant to drug delivery. These include layer number, surface area, lateral dimensions, and surface chemistry. It has a high surface area of 2,600m2g-1 that allows high drug loading capacity compared to other nano-materials.
The success of a drug delivery system based on graphene oxide depends on three factors which we have taken into consideration. The first is developing a carrier with an optimal loading capacity; the second is verifying the degree of its compatibility with the body and level of toxicity; the third is to create a system that will release the drugs in a controlled pattern at the specific site (tumor).
We have taken all these into consideration, creating a system that can conjugate the drugs with specific ligands such as transferrin, folic acid and polyclonal antibodies that can recognize molecular signatures on the target surface.
With our advanced technology, we have created a graphene oxide-based delivery system with a:
- High specificity and affinity
- Little to no side effects
- A low effective dose
- Less chances of cancer cells developing a resistance to the therapy, giving room to effective treatment and prognosis.
With the use of our graphene-oxide formulation, a greater concentration of anticancer drug can be lodged in the cancer cell while bypassing healthy cells. We have done series of researches and have verified that graphene oxide poses no threat to healthy cells, but just cancer cells. Hence, we have formulated it in such a way that it targets just the cancer cells.
We are committed to doing more researches to get the best therapy for cancer.
